Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 172 Records) |
| Query Trace: Neoplasms and DPYD[original query] |
|---|
| Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase. Clinical and translational science 2021 12 15 (5): 1104-1111. Kang Jihyun, Kim Andrew HyoungJin, Jeon Inseung, Oh Jaeseong, Jang In-Jin, Lee SeungHwan, Cho Joo-Yo |
| Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. Pharmaceutics 2021 12 13 (12): . Soria-Chacartegui Paula, Villapalos-García Gonzalo, López-Fernández Luis A, Navares-Gómez Marcos, Mejía-Abril Gina, Abad-Santos Francisco, Zubiaur Pab |
| Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. Mutation research. Reviews in mutation research 2021 12 788 108391. Cura Yasmin, Pérez Ramírez Cristina, Sánchez Martín Almudena, Martínez Martínez Fernando, Calleja Hernández Miguel Ángel, Ramírez Tortosa María Del Carmen, Jiménez Morales Alber |
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer. Asian Pacific journal of cancer prevention : APJCP 2022 Sep 23 (9): 3061-3069. Almashagbah Nusaiba A, Mahasneh Amjad A, Bodoor Khaldon |
| DPYD and TYMS polymorphisms as predictors of 5 fluorouracil toxicity in colorectal cancer patients. Journal of chemotherapy (Florence, Italy) 2022 Sep 1-10. Khalij Yassine, Belaid Imtinen, Chouchane Sana, Amor Dorra, Omezzine Asma, Ben Rejeb Nabila, Ben Ahmed Slim, Bouslama A |
| Detection of relevant pharmacogenetic information through exome sequencing in oncology. Pharmacogenomics 2022 8 23 (14): 759-770. Verdez Simon, Albuisson Juliette, Duffourd Yannis, Boidot Romain, Reda Manon, Thauvin-Robinet Christel, Fumet Jean-David, Ladoire Sylvain, Nambot Sophie, Callier Patrick, Faivre Laurence, Ghiringhelli François, Picard Nicol |
| Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase. Cancer drug resistance (Alhambra, Calif.) 2022 5 2 (3): 787-802. Merloni Filippo, Ranallo Nicoletta, Scortichini Laura, Giampieri Riccardo, Berardi Rossa |
| Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022 4 45 (7): 5-10. Riera Pau, Riba Mireia, Bernal Sara, Virgili Anna C, Páez David, Moreno M Este |
| Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. JCO oncology practice 2022 3 18 (6): e958-e965. Koo Kyoin, Pasternak Amy L, Henry N Lynn, Sahai Vaibhav, Hertz Daniel |
| Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature cancer 2022 2 1 (4): 452-468. Pleasance Erin, Titmuss Emma, Williamson Laura, Kwan Harwood, Culibrk Luka, Zhao Eric Y, Dixon Katherine, Fan Kevin, Bowlby Reanne, Jones Martin R, Shen Yaoqing, Grewal Jasleen K, Ashkani Jahanshah, Wee Kathleen, Grisdale Cameron J, Thibodeau My Linh, Bozoky Zoltan, Pearson Hillary, Majounie Elisa, Vira Tariq, Shenwai Reva, Mungall Karen L, Chuah Eric, Davies Anna, Warren Mya, Reisle Caralyn, Bonakdar Melika, Taylor Gregory A, Csizmok Veronika, Chan Simon K, Zong Zusheng, Bilobram Steve, Muhammadzadeh Amir, D'Souza Darryl, Corbett Richard D, MacMillan Daniel, Carreira Marcus, Choo Caleb, Bleile Dustin, Sadeghi Sara, Zhang Wei, Wong Tina, Cheng Dean, Brown Scott D, Holt Robert A, Moore Richard A, Mungall Andrew J, Zhao Yongjun, Nelson Jessica, Fok Alexandra, Ma Yussanne, Lee Michael K C, Lavoie Jean-Michel, Mendis Shehara, Karasinska Joanna M, Deol Balvir, Fisic Ana, Schaeffer David F, Yip Stephen, Schrader Kasmintan, Regier Dean A, Weymann Deirdre, Chia Stephen, Gelmon Karen, Tinker Anna, Sun Sophie, Lim Howard, Renouf Daniel J, Laskin Janessa, Jones Steven J M, Marra Marco |
| Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population. Cancer medicine 2022 12 . Kanai Masashi, Kawaguchi Takahisa, Kotaka Masahito, Manaka Dai, Hasegawa Junichi, Takagane Akinori, Munemoto Yoshinori, Kato Takeshi, Eto Tetsuya, Touyama Tetsuo, Matsui Takanori, Shinozaki Katsunori, Matsumoto Shigemi, Mizushima Tsunekazu, Mori Masaki, Sakamoto Junichi, Ohtsu Atsushi, Yoshino Takayuki, Saji Shigetoyo, Matsuda Fumihi |
| Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays. International journal of molecular sciences 2022 11 23 (22): . De Luca Ottavia, Salerno Gerardo, De Bernardini Donatella, Torre Maria Simona, Simmaco Maurizio, Lionetto Luana, Gentile Giovanna, Borro Mari |
| Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma in Japanese patients using a novel panel for cancer-related drug-metabolizing enzyme genes. Scientific reports 2022 10 12 (1): 17928. Ohnami Sumiko, Naruoka Akane, Isaka Mitsuhiro, Mizuguchi Maki, Nakatani Sou, Kamada Fukumi, Shimoda Yuji, Sakai Ai, Ohshima Keiichi, Hatakeyama Keiichi, Maruyama Kouji, Ohde Yasuhisa, Kenmotsu Hirotsugu, Takahashi Toshiaki, Akiyama Yasuto, Nagashima Takeshi, Urakami Kenichi, Ohnami Shumpei, Yamaguchi K |
| Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations. Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1400-1405. Paulsen Niels Herluf, Qvortrup Camilla, Vojdeman Fie Juhl, Plomgaard Peter, Andersen Stig Ejdrup, Ramlov Anne, Bertelsen Birgitte, Rossing Maria, Nielsen Claus Gyrup, Hoffmann-Lücke Elke, Greibe Eva, Spangsberg Holm Hanne, Nielsen Heidi Hvid, Lolas Ihab Bishara Yousef, Madsen Jonna Skov, Bergmann Marianne Lerbaek, Mørk Morten, Fruekilde Palle B Nielsen, Bøttger Pernille, Petersen Peter Clausager, Nissen Peter Henrik, Feddersen Søren, Bergmann Troels K, Pfeiffer Per, Damkier P |
| Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer. International journal of cancer 2022 Oct . Ma Yueyun, Li Wenjie, Chen Shiyu, Lin Shuimiao, Ding Sijie, Zhou Xiaomei, Liu Tongxin, Wang Rong, Wang W |
| Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer 2022 1 128 (8): 1649-1657. Reizine Natalie M, Danahey Keith, Truong Tien M, George David, House Larry K, Karrison Theodore G, van Wijk Xander M R, Yeo Kiang-Teck J, Ratain Mark J, O'Donnell Peter |
| Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia. Frontiers in pharmacology 2023 9 14 1257745. Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J D Ross, Bruce C Carlet |
| Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients. Pharmacogenetics and genomics 2023 8 . Manuela Pinheiro, Ana Peixoto, Patrícia Rocha, Catarina Santos, Carla Escudeiro, Isabel Veiga, Miguel Porto, Joana Guerra, Ana Barbosa, Carla Pinto, Patrícia Arinto, Adriana Resende, Manuel R Teixei |
| DPD deficiency in an Irish oncology centre: Prevalence and clinical implications. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 8 10781552231192107. Ruth Kieran, Taylor Mitchell, Afrah Al Fazari, Aleena Chinoy, Carolyn Moloney, John McCaffr |
| Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study. Cancers 2023 7 15 (13): . Matteo Conti, Elena Bolzacchini, Giovanna Luchena, Lorenza Bertu', Paola Tagliabue, Stefania Aglione, Antonio Ardizzoia, Jessica Arnoffi, Francesco Maria Guida, Alessandro Bertolini, Alessandro Pastorini, Maria Duro, Donato Bettega, Giovambattista Roda', Salvatore Artale, Alessandro Squizzato, Monica Giorda |
| Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy. International journal of molecular sciences 2023 6 24 (12): . Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos, Oliver Higuera, Alberto M Borobia, Sonia Rodriguez-Novoa, Javier de Castro-Carpeño, Inmaculada Ibanez de Caceres, Rocio Rosas-Alon |
| Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis. Value in health regional issues 2023 6 37 71-80. Soroush Ahmadi Fariman, Zahra Jahangard Rafsanjani, Mandana Hasanzad, Kimia Niksalehi, Shekoufeh Nikf |
| Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients. Pharmacogenomics 2023 5 . Abdullah Alsulaiman, Hoyin Chu, Mohammed Al-Jumaan, Mohammed Alyahya, Yousef Al Marzooq, Fatmah Almulhim, Chittibabu Vatte, Areej Alnimer, Afnan Almuhanna, Amein Al-Ali, Saud H AlDubay |
| Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. The oncologist 2023 4 . Miarons Marta, Manzaneque Gordón Alba, Riera Pau, Gutiérrez Nicolás Fernando, |
| Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe. Journal of personalized medicine 2023 4 13 (4): . Boluwatife Lawrence Afolabi, Tinashe Mazhindu, Chikwambi Zedias, Margaret Borok, Ntokozo Ndlovu, Collen Masimirembwa, On Behalf Of Consortium For Genomics And Therapeutics In Africa Cg |
| Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC cancer 2023 4 23 (1): 380. David K Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starli |
| The role of gender pharmacogenetics in the personalization of drug treatment. The Journal of pharmacology and experimental therapeutics 2023 3 . Cecchin Erika, Posocco Bianca, Mezzalira Silvia, Appetecchia Marialuisa, Toffoli Giusep |
| Implementation and clinical benefit of DPYD genotyping in a Danish cancer population. ESMO open 2023 2 8 (1): 100782. Paulsen N H, Pfeiffer P, Ewertz M, Fruekilde P B N, Feddersen S, Holm H S, Bergmann T K, Qvortrup C, Damkier |
| Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece. Frontiers in pharmacology 2023 10 14 1248898. Georgia Ragia, Anthi Maslarinou, Natalia Atzemian, Eirini Biziota, Triantafyllia Koukaki, Charalampia Ioannou, Ioanna Balgkouranidou, George Kolios, Stylianos Kakolyris, Nikolaos Xenidis, Kyriakos Amarantidis, Vangelis G Manolopoul |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: